Side Effect Patterns in a Crossover Trial of Statin, Placebo, and No Treatment

Howard, James P., Wood, Frances A., Finegold, Judith A., Nowbar, Alexandra N., Thompson, David M., Arnold, Ahran D., Rajkumar, Christopher A., Connolly, Susan +7 more·2021·Journal of the American College of Cardiology

DOI 10.1016/j.jacc.2021.07.022

Cited by (200)

Items 101–200 of 200

Statin related muscle symptoms: is it time to move on
Safi Ullah Khan, Neal S. Kleiman · 2022 · BMJ
Patient-reported muscle symptoms and their characterization in a hypertensive population eligible for statin therapy: An exploratory study
Riccardo Sarzani, Massimiliano Allevi, Federico Giulietti, Silvia Sarnari, Samuele Scorcella, Angelica Di Agostini, Paolo Turri, Chiara Di Pentima, Francesco Spannella · 2023 · Nutrition Metabolism and Cardiovascular Diseases
Statin-associated muscle symptoms: Myth or reality?
Arturo Muñoz Blanco, Ricardo Gómez-Huelgas, J.F. Gómez-Cerezo · 2022 · Revista Clínica Española (English Edition)
Temporary Like Achilles: Pre‐emptive germline pharmacogenetic testing
Per Damkier, Michael Asger Andersen · 2023 · Basic & Clinical Pharmacology & Toxicology
Patient perspectives on statin intolerance, attribution of the nocebo effect and use of N=1-interventions: a qualitative focus group study
Ruben J M Mijnster, Marte F. van der Bijl, Amber Niesthoven, Leonieke W. Kranenburg, P.H.M. van der Kuy, Inge Merkelbach, Melvin Lafeber, Jeanine E. Roeters van Lennep · 2025 · Atherosclerosis
An intensive, structured, mobile devices-based healthcare intervention to optimize the lipid-lowering therapy improves lipid control after an acute coronary syndrome
Sonia Ruiz, Neus Badosa, Ignacio Cabrera-Aguilera, Consol Ivern, Marc Llagostera, Diana Mojón, Miren Vicente, Núria Ribas, Lluís Recasens, Julio Martí‐Almor et al. · 2022 · Frontiers in Cardiovascular Medicine
Statin withdrawal and health-related quality of life in a primary cardiovascular prevention cohort
Paul Peyrel, Pascale Mauriège, Jérôme Frenette, N Laflamme, Karine Greffard, Claire Huth, Jean Bergeron, Denis R. Joanisse · 2023 · Quality of Life Research
Achievement of LDL‐Cholesterol Goals in Patients Receiving LLT in Primary Care: TERESA‐AP Study: LDL‐Cholesterol Goals in Primary Care
Cinza-Sanjurjo, Sergio, Barrios, Vivencio, Fierro-González, David, Polo-García, Jose, Pallarés-Carratalá, Vicente · 2024 · Cardiovascular Therapeutics
Statin-associated muscle symptoms in the VITamin D and OmegA-3 TriaL (VITAL)
Pedro A. Engel Gonzalez, Mark Andrew Hlatky, JoAnn E. Manson, Julie E. Buring, I-min M Lee, Nancy R. Cook, Vadim Y. Bubes, Neil J. Stone · 2022 · American Heart Journal
Significance of Statin-Associated Muscle Symptoms and Its Impact on Patients Adherence and Outcomes
Hanna K. Al-Makhamreh, Ahmad A. Toubasi, Yazan Y. Obaid, Farah H. Albustanji · 2022 · Journal of Cardiovascular Pharmacology
The General View of Virtual Reality Technology in the Education Sector
Ghaliya Muslem ALFarsi, Azmi bin Mohd. Yusof, Ragad Moufaq Tawafak, Sohail Iqbal Malik, Abir AlSideiri, Roy Mathew, Maryam Alsinani · 2023 · Algorithms for intelligent systems
Efficacy for LDL-C–lowering and safety of pemafibrate extended-release formulation in patients with statin-intolerant hypercholesterolemia: A phase 3 multicenter, randomized, double-blind, placebo-controlled, parallel-group trial
Shizuya Yamashita, Eiichi Araki, Hidenori Arai, Koutaro Yokote, Ryohei Tanigawa, Keisuke Kunitomi, Kaho Ikegami, Hideki Suganami, Masaya Tanahashi, Sara Minamikawa et al. · 2026 · Journal of clinical lipidology
Sex Differences in Statin Intolerance: Insights From the CLEAR Outcomes Trial
Sahar Naderi, Danielle M. Brennan, Na Li, Abraham Michael Lincoff, Stephen James Nicholls, Steven E. Nissen, Jorge Plutzky, Heather A. Powell, Paula L. Robinson, Leslie Cho · 2026 · Clinical Cardiology
Placebo immune-related adverse events (irAEs): A neglected phenomenon in cancer immunotherapy trials
Yixin Zhou, Hui Yu, Chen Chen, Anlin Li, Xuanye Zhang, Huijuan Qiu, Wei Du, Sha Fu, Li Zhang, Shaodong Hong · 2024 · European Journal of Cancer
Revisiting ecological fallacy: are single-case experimental study designs even more relevant in the era of precision medicine?
Theodoros Christophides, Maria Karekla · 2024 · Precision Clinical Medicine
COVID-19 vaccine hesitancy and perceived post-vaccination adverse event: Findings from a cross-sectional survey
Maude Dionne, Chantal Sauvageau, Jeremy Keith Ward, Jérémie Sylvain-Morneau, Fátima Gauna, Radhouene Doggui, Ève Dubé · 2025 · Vaccine
Incidence of muscle symptoms in placebo arm among statin-intolerant patients: a systematic review with meta-analysis
Rita Louro, Ryan Gouveia e Melo, Jorge Ruivo, Ana G. Almeida, Fausto José Pinto, Daniel Caldeira · 2023 · Expert Review of Cardiovascular Therapy
Why Do I Get Side Effects? Personalized (N-of-1) Trials for Statin Intolerance and the Nocebo Effect
James Philip Howard, Frances A. Wood, Dárrel P. Francis · 2022 · Harvard Data Science Review
Lipid lowering in primary prevention: time to focus on young patients
Ahmad Hayek, Guillaume Marquis‐Gravel · 2022 · Heart
Development and Validation of the Pharmacological Statin‐Associated Muscle Symptoms Risk Stratification Score Using Electronic Health Record Data
Boguang Sun, Pui Ying Yew, Chih‐Lin Chi, Meijia Song, Matt Loth, Yue Liang, Rui Zhang, Robert J. Straka · 2024 · Clinical Pharmacology & Therapeutics
Comparison of rosuvastatin 10 mg plus ezetimibe versus rosuvastatin 20 mg in atherosclerotic cardiovascular disease and type 2 diabetes
Hyo‐In Choi, Seung Jin Oh, Yun Hyeong Jo, Yong Hwan Park, Yong Hyun Park, Tae‐Hyun Yang, Joon‐Hyung Doh, Young Joon Hong, Kye Taek Ahn, Jin Man Cho et al. · 2025 · Scientific Reports
Evaluating genotype–treatment interactions for high-risk medications in British general practice: a retrospective cohort study using UK Biobank
Kinan Mokbel, Michael N. Weedon, ROB DANIELS, Victoria Moye, Leigh M. Jackson · 2025 · British Journal of General Practice
Addressing Disparities in the Screening and Treatment of Dyslipidemia – A Call to Action
Emily Converse, Karol Watson, Zahid Ahmad, Eugene Yang, Eugenia Gianos, Usman Sagheer, Salim S. Virani, Dinesh Kumar Kalra · 2025 · Current Cardiovascular Risk Reports
Large Language Model–Based Analysis of Statin Therapy Discussions and Sentiment on Social Media: Cross-Sectional Observational Study
Siru Liu, Jialin Liu · 2026 · Journal of Medical Internet Research
Lipid clinics worldwide: harmonization and guidance on how to optimally organize and fund. European Atherosclerosis Society consensus statement across 55 countries and more than 500 lipid clinics
Christian Bork, Børge Grønne Nordestgaard, Berit Storgaard Hedegaard, Michal Vrablik, Elsie Evans, Tomáš Freiberger, Zlatko Fras, David Nanchen, Fouzia Sadiq, Kausik Kumar Ray et al. · 2026 · Atherosclerosis
Unused potential of lipid-lowering therapy in very high-risk patients with atherosclerotic cardiovascular disease. A retrospective data analysis
S Pohl, Christiane M. Engelbertz, Holger Reinecke, Nasser M. Malyar, Matthias Meyborg, Tobias Johannes Brix, Julian Varghese, Katrin Gebauer · 2024 · Nutrition Metabolism and Cardiovascular Diseases
OS TIPOS DE TRATAMENTOS ATUALMENTE DISPONÍVEIS PARA DISLIPIDEMIA E CONTROLE DOS TRIGLICERÍDEOS
Daniela Rodrigues Nogueira, Gabriel Chehab de Carvalho Melo, Ivy de Almeida Cavalcante e Silva, Luiz Eduardo Pinheiro Moreira, Magda de Souza Barbeiro Pedrosa, Márcia de Paula Cardinali, Priscylla Lima Viscone Peron, Roberta Gomes Piazzi · 2024 · EPITAYA eBooks
Statin intolerance and the drucebo effect
B Mugawar, Sarah McErlean, P. O. Connor, Cormac Kennedy · 2024 · QJM
Harnessing n-of-1 trials for personalised paediatric care in the era of information overload
Joyce P. Samuel · 2025 · The Lancet Child & Adolescent Health
Case Report: Practical approach to unmask unspecific adverse effects under lipid-lowering medication
Thomas Büttner, Gunther Hartmann, Martin Coenen · 2025 · Frontiers in Cardiovascular Medicine
Female patients with vascular disease receive less medical optimization despite more health care utilization
Mikayla N. Lowenkamp, Hasan Nassereldine, Alexas Iams, Edith Tzeng, Katherine Moll Reitz · 2025 · Journal of Vascular Surgery
Statin therapy during pregnancy
Paulina Elena Stürzebecher, Ulrich Laufs · 2025 · European Heart Journal
Harnessing the power of placebos and mitigating nocebo effects in clinical practice
Sara A. Wettergreen, Ardath Plauche, Morgan P. Stewart · 2022 · JACCP JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY
Effects of nocebo and drusebo in determining statin-induced muscle symptoms
Леонова Марина Васильевна · 2022 · Meditsinskiy sovet = Medical Council
Sintomatología muscular asociada a estatinas: ¿mito o realidad?
Arturo Muñoz Blanco, Ricardo Gómez-Huelgas, J.F. Gómez-Cerezo · 2022 · Revista Clínica Española
Management of cardiometabolic diseases: A clinician's perspective
Nikhil S. Bassi, Poornima Mohan, Dipti Itchhaporia · 2024 · Elsevier eBooks
Statins as potential adjuvant therapy in lung cancer: a narrative review
Ye Tian, Jinbao Li, Xueying Yang · 2025 · Journal of Thoracic Disease
Shared Decision-Making for Restoring Trust in the Management of Atherosclerotic Cardiovascular Disease in the Post-pandemic Era
Warren J Wexelman, Nicole A. Ciffone, Nishant P. Shah · 2025 · Advances in Therapy
Progress in risk assessment and management: Forecasting updates across international cholesterol guidelines
Alexander C. Razavi, Mark Sokolsky, Matthew Belanger, Cameron M. Blazoski, Jared Alexander Spitz, Laurence S. Sperling, Roger Scott Blumenthal, Seamus Paul Whelton · 2026 · American Journal of Preventive Cardiology
Population prevalence of suboptimal statin use: Considering guidelines and patient preference
Alexander Chaitoff, Jeremy B. Sussman, Kathryn Anne Martinez, Alexander R. Zheutlin · 2026 · American Journal of Preventive Cardiology
Statins, LDL-C and Beyond: A Contemporary Review of Atherosclerotic Cardiovascular Risk Assessment and Management
Andrew James Fancher, Angel López‐Candales, Khalid Sawalha · 2026 · Journal of Lipid and Atherosclerosis
Transient Ischaemic Attack in a Patient With Conn Syndrome: A Case Report and Literature Review on the Importance of Identifying Secondary Hypertension
Daniel C. Lee, KATE EMBLIN, ROB DANIELS, Tomazo Joseph Kallis, MOHAMMAD ALALLAN, Kinan Mokbel · 2024 · In Vivo
Statin associated muscle symptoms in older adults
Elizabeth K. Pogge, Nicole K. Early · 2025 · Expert Review of Clinical Pharmacology
Clinician-level variation in lipid management for secondary prevention of atherosclerotic cardiovascular disease: Opportunities for practice improvement
Danh Q. Nguyen, Jimin Hwang, Anand K. Rohatgi, Parag H. Joshi, Amit Khera, Eric David Peterson, Ann Marie Návar · 2026 · American Journal of Preventive Cardiology
Association between three lipid-lowering drugs and amnesia: a real-world pharmacovigilance study
Jingyi Chen, Yang Wu, Yan Liu, Xingquan Zhai, Yang Xu, Xiaogang Tang, Qing Zhu, Zhaoyao Chen, Wenlei Li, Yuan Zhu et al. · 2026 · Naunyn-Schmiedeberg s Archives of Pharmacology
Secondary prevention strategies for patients with lower extremity peripheral artery disease after successful peripheral vascular intervention
Pishoy Gouda, Eric Alexander Secemsky, Connie Ng Hess, Shipra Arya, Foluso Fokorede, Roxana Mehran, Marc P. Bonaca, Manesh R. Patel, W Schuyler Jones · 2026 · American Heart Journal
Statin-Associated Muscle Symptoms and Myotoxicity: A Clinically Oriented Narrative Review with a Practical Prevention, Evaluation, and Management Algorithm
Francisco Epelde · 2026 · Medicina
Review of the top 5 cardiology studies of 2021-22
Arden R. Barry, Rosaleen Boswell, Hazal E. Babadagli, June W. Chen, Dylan M. Pollmann, Jian Song Zhou · 2023 · Canadian Pharmacists Journal / Revue des Pharmaciens du Canada
Modern prospects of targeted hypolipidemic therapy
Alexey N. Kuchmin, Нагорный Михаил Борисович, Anatoly M. Grachev, Елена Витальевна Смирнова · 2023 · Bulletin of the Russian Military Medical Academy
Bempedoic Acid: Safety and Efficiacy of a New Lipid-Lowering Agent
И. А. Мазеркина, Татьяна Михайловна Букатина, T. V. Aleksandrova · 2023 · Safety and Risk of Pharmacotherapy
Top 10 Tips for Using Statins in Clinical Practice
Sean M. Rangwani, Jennifer Maning, Neil J. Stone · 2024 · Mayo Clinic Proceedings
Rationale and design of VICAD-RISK study: Visualization of coronary artery disease for modification of risk factors
Archana Kulasingam, Sussie Laustsen, Martin Busk, Niels Peter Rønnow Sand, Simon Winther, Kristian Hay Kragholm, Osama Hammid, Kamilla Bech Pedersen, Peter Vedsted, Helle Kanstrup et al. · 2025 · American Heart Journal
Prevalence of constipation and associated factors among patients with heart disease: A cross-sectional survey
Amanda Cigarlos Dahlmann, Hanne Konradsen, Signe Stelling Risom, Trine Bernholdt Rasmussen · 2022 · Nordisk Sygeplejeforskning
Angiotensin-converting enzyme inhibitors, statins and the polypill in cardiovascular diseases prevention: ignorance is bliss or not?
Francesco Natale, Paolo Golino, Giovanni Cimmino · 2024 · Journal of Hypertension
Time to Move Beyond the Statin Nocebo Effect
Harlan M. Krumholz · 2026 · Journal of the American College of Cardiology
Safety outcomes of statin vs non-statin lipid-lowering interventions in patients with prior statin-associated muscle symptoms: A systematic review and meta-analysis
Aebi, Philipp Stefan, Villoz, Fanny, Bührer, Jonas, Lyko, Christina, Abolhassani, Nazanin, Del Giovane, Cinzia, Gencer, Baris, Rodondi, Nicolas, Blum, Manuel R. · 2025 · PLOS One
Role of Blinding in N-of-1 Trials
James P. Howard, Skanda Rajasundaram · 2022 · Circulation Cardiovascular Quality and Outcomes
Risk of muscle symptoms while taking statins
Jamie Falk, Allison Paige, Nicolas Dugré, Gary Michael Allan · 2023 · Canadian Family Physician
Risque de symptômes musculaires avec la prise de statines
Jamie Falk, Allison Paige, Nicolas Dugré, Gary Michael Allan · 2023 · Canadian Family Physician
Statin-induced myopathy: A rare entity?
Théo Wirth, Sandrine Guis · 2023 · Joint Bone Spine
Novel approaches to the management of hyperlipidaemia
Anna Kate Barton · 2023 · Prescriber
A critical look at the new possibilities of therapeutic use of statins – a summary of the current state of knowledge
Kacper Kossakowski, Klaudia Orzechowska, Weronika Sikora, Wiktoria Grabowska, Kornelia Kowalska, Radosław Kujawski, Kamila Czora-Poczwardowska, Michał Szulc, Przemysław Łukasz Mikołajczak, Joanna Bartkowiak-Wieczorek · 2023 · Farmacja Polska
The Christmas adverse event syndrome: An analysis of the WHO pharmacovigilance database
Alex Hlavaty, Matthieu Roustit, Marc Manceau, Jean‐Luc Cracowski, Charles Khouri · 2023 · Therapies
Statins: 30 years after the landmark 4S study
Mark Greener · 2024 · Prescriber
Statine: Nebenwirkungen – alternative Therapieoptionen
Umidakhon Makhmudova, Oliver Weingärtner · 2024 · Die Kardiologie
Myopathies induites par les statines : une entité rare ?
Théo Wirth, Sandrine Guis · 2024 · Revue du Rhumatisme
Statin uses and skeletal muscle-related phenotypes: insights from epidemiological and Mendelian randomization analyses
Fan Tang, Zhanchao Chen, Hongbin Qiu, Yige Liu, Yanjiao Shen, Yiying Zhang, Shanjie Wang, Bo Yu · 2024 · medRxiv
Dyslipidemia
Laura J. Ross · 2025 · Physician Assistant Clinics
Statins as a risk factor for anaemia: Evidence from genetic and epidemiological data
Zhekang Liu, Qingan Fu, Junda Cao · 2025 · British Journal of Clinical Pharmacology
Licochalcone a Attenuates High-Fat Diet-Induced Obesity by Regulating Gut Microbiome and Histidine Metabolism
E‐Hu Liu, Zebin Weng, Xin Yu Ji, Zhipeng Dai, Jin Zhu, Lin-Feng Lu, ZhengMeng Jiang · 2025 · SSRN Electronic Journal
Rhabdomyolysis Related to High-dose Atorvastatin: A Case Report
Mrutyunjaya Behera, Priyadarsi Tripathy · 2025 · Journal of the Association of Physicians of India
Novel therapies for lowering low-density lipoprotein levels for atherosclerotic cardiovascular disease prevention: reaching the target where others have failed
Artur Dziewierz, Beata Bobrowska, Witold Streb, Francesco Pelliccia, Stanisław Bartuś, Renata Rajtar-Salwa · 2025 · Expert Review of Cardiovascular Therapy
Long‐Term Adherence and Drug Utilisation Patterns Among New Users of Anti‐Hyperlipidemic Monotherapy: Development of a Risk Prediction Model
Xuechun Li, Eelko Hak, Jens Bos, Catharina C. M. Schuiling‐Veninga, Sumaira Mubarik · 2026 · Journal of Evaluation in Clinical Practice
Sleep effects of hydrophilic and lipophilic statins: a comparative narrative review of clinical and experimental evidence
Sofia Salari, Yasamin Moeinipour, Ghazaleh Elahabadi, Aliasghar Moeinipour, Amir Hooshang Mohammadpour · 2026 · Behavioural Pharmacology
Management of a patient with a ticagrelor–rosuvastatin interaction: An algorithm-based tool kit for pharmacists
Keren-Happauch Emekeme, Kirsten Tangedal, William Semchuk, Joyce Goldak, Kayla Bannouvong · 2026 · Canadian Pharmacists Journal / Revue des Pharmaciens du Canada
Dyslipidaemia and cardiovascular risk – Key considerations in South Asians
Aneesha Chauhan, Shaan Sahota, Lavandan Jegatheeswaran, Haneesh Kaur Johal, Rubin Minhas, Prashanth Patel, Pankaj Gupta, Vinod Patel, Amitava Banerjee, Kiran Patel et al. · 2026 · Clinical Medicine
Unmet needs for lipid management in patients with peripheral arterial disease: A narrative review
Demetria M Bolden, Mary Katherine Cheeley, Barry Craig Tedder · 2026 · Journal of clinical lipidology
2026 Taiwan Society of Lipids and Atherosclerosis consensus statement for the identification and management of patients receiving suboptimally tolerable statins
Yih‐Jer Wu, Chih‐Fan Yeh, Chien-Yi Hsu, C Y Lin, Chun‐Yao Huang, Sung‐Chun Tang, Y T Huang, C Y Lin, Chi-Hua Yu, Chun Yao Huang et al. · 2026 · Journal of the Formosan Medical Association
Lipid lowering in coronary artery disease – not just statins
Jennie Han, Eva Masmanian, Timothy Wang, Tuan Peng Chua · 2026 · Clinical Medicine
Placebo- und Noceboeffekte in der Herzmedizin: die Bedeutung von Erwartungen für den Behandlungserfolg
Stefan Salzmann, Miriam Salzmann-Djufri, Marcel Wilhelm · 2026 · Kardiologie up2date
Shaping expectations in care: A scoping review of experimental and clinical evidence on communication strategies to reduce the nocebo effect
Sheng-Kang Peng, Pin-Heng Tiao, Hsun‐Yu Chan, Yen‐Ming Huang · 2026 · Patient Education and Counseling
N=1-studies In Statin-intolerance; Objectifying Nocebo Effects (NISONE): a study protocol for a randomised controlled trial assessing the implementability of N=1-studies to promote the use of statins
Ruben J M Mijnster, Jeanine E. Roeters van Lennep, Wim J. R. Rietdijk, Kübra Akgöl, Elles Marleen Kemper, Daniëlle T.N.A. van den Berg, P.H.M. van der Kuy, Melvin Lafeber · 2026 · BMJ Open
Potential Biases in Assessment of Smallest Worthwhile Difference for Statin Therapy
Brett G. Fischer · 2026 · JAMA Internal Medicine
Statin Therapy and Cardiovascular Prevention: Contemporary Evidence, Challenges, and Future Directions—A Narrative Review
Don Zachariah, Dominic Kakooza, Sharifa Pothas, Anjana Thomas, Iolanthé M. Kruger · 2026 · International Journal of Environmental Research and Public Health
New insights into statin-intolerance: biopsychosocial differences, medication beliefs, trust in healthcare, and treatment decisions in statin-intolerant vs. statin-tolerant patients
Ruben J M Mijnster, Neivyn Shaheen, Wim J. R. Rietdijk, Fabrice M A C Martens, Remy H.H. Bemelmans, Inge Merkelbach, P.H.M. van der Kuy, Melvin Lafeber, Jeanine E. Roeters van Lennep · 2026 · European Journal of Preventive Cardiology
Frequency of Myopathy with Statins Given for Secondary Prevention of Myocardial Infarction
Masoom Qasim, Azfar Farogh, Zarmina Younes, Masooma Naqvi · 2025 · Indus journal of bioscience research.
Beyond LDL-C: Modern Lipid Management for ASCVD Prevention in Primary Care
Andrew M. Carlson, Zaid A. Zayyad, Stefanie Driesenga, Peter Boxley, Atreya Mishra, Omar Uraizee, Rediat Ephrem, Runze Zhang, Zachary Natsheh, Adhir Ramesh Shroff · 2026 · Cardiology and Therapy
Informing the patient of the placebo option: an ethical necessity likely to reduce inappropriate psychotropic prescriptions?
Fabrice Sébastien Berna, Guillaume Durand, Rémy Boussageon, Julien Nizard, François Paillé, L. Verneuil · 2026 · Therapeutic Advances in Psychopharmacology
Statins Use in Veterans With Peripheral Artery Disease: Insights From the PEARLS Study
Rohit Nathani, Cathy Nguyen, Qiang Li, Mary Vaughan‐Sarrazin, Mohammed Ali Al-Garadi, Nicole Minniefield‐Young, Kim G. E. Smolderen, Shirling X. Tsai, Shipra Arya, Joshua A. Beckman et al. · 2026 · Circulation Population Health and Outcomes
Pharmacological management of atherosclerotic cardiovascular disease risk: a narrative of lipid-lowering pharmacotherapy and the LDL-cholesterol dose-response relationship
Dr. Makbul Hussain Choudhury · 2025 · Journal of Prevention Diagnosis and Management of Human Diseases
Deprescribing statins for adults 65 years of age and older
Wade Thompson, Arden R. Barry, Lisa M. McCarthy, Jeffrey Pan, Cayden Peixoto, Geneviève Lemay, Parag Goyal, Celeste Fung, Dar D Dowlatshahi, Johanna Trimble et al. · 2026 · Canadian Family Physician
Rational Prescribing Under Diagnostic Uncertainty Requires Explicit Therapeutic Trials, Reassessment Thresholds, and Stopping Rules
Carlos Mendoza, Aisha Rahman · 2023 · Annals of Pharmacy Practice and Pharmacotherapy
Risk Communication Can Produce the Nonadherence It Seeks to Prevent Through Nocebo Effects, Numerical Framing, Unresolved Uncertainty, and Loss of Patient Control
Laura Mendez, Hiroshi Sato, Anna Weber · 2024 · Annals of Pharmacy Practice and Pharmacotherapy
Changes in statin therapy following discharge in those with cardiovascular disease in Ireland
Cillian O’Brien, Greg Murphy, David A. Wood, C McCaughey · 2026 · Irish Journal of Medical Science (1971 -)
Residual atherosclerotic cardiovascular disease risk in statin-treated patients: mechanisms, therapeutic strategies, and future directions—a scoping review
Muhammad Abdul Rehman, Malik Olatunde Oduoye, Davidson John Ozoemena, Edward Akosah Danso, Gabriel Chukwuka, Mary Abosede Odelade · 2026 · Frontiers in Cardiovascular Medicine
Atorvastatin Safety Reappraised: From Pharmacogenomic Mechanisms to Personalized Risk Management
Hanyu Wang, Yue Pan, Yiming Li, Pan Zhai · 2026 · Cardiovascular Therapeutics
Diagnostic Communication and the Care That Follows: A Critical Narrative Review
Theodoros T Xanthos · 2026 · Diagnostics
Bottlenecks in cardiovascular prevention: Can artificial intelligence close the gap?
Gauthier Beuque, Jean-Baptiste de Fréminville, Alexandre Boutigny, Josselin Duchâteau, Benoît Lequeux, Atul Pathak, Guillaume Bailly, Romain Boulestreau · 2026 · Archives of cardiovascular diseases
Does Adding Nocebo Avoidance Strategies Increase the Strength of Nocebo Education?
Emily K Spotts, Andrew L. Geers · 2026 · European Journal of Health Psychology
Statin Intolerance, Treatment Gaps, and Cardiovascular Outcomes: A 24‐Year Health System Analysis
Kelvin Supriami, Elie W. Akl, Roukoz Abou-Karam, Abigail G. Thompson, Micaela Yudelman, Steven J. Atlas, Patrick T. Ellinor, Akl C. Fahed · 2026 · Journal of the American Heart Association